Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (511-520 of 610) with videos related to

Pageof 61
Sort By:
Neurosurgery|July 17, 2018
Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype GlioblastomaDrew Pratt, Gifty Dominah, Graham Lobel, et al.
Leukemia Research|August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles, Eric J Feldman, Gail J Roboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemiaH M Kantarjian, S O'Brien, T L Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responsesJorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Cancer|February 6, 2003
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Leukemia|July 16, 2011
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaJ E Lancet, F Ravandi, R M Ricklis, et al.
Leukemia|December 14, 2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, et al.
The Oncologist|March 15, 2019
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung CancerYoung Kwang Chae, Andrew A Davis, Sarita Agte, et al.
Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levelsDevalingam Mahalingam, Ernest C Medina, Juan A Esquivel, et al.
Pageof 61

Showing results (511-520 of 610) with videos related to

Sort By:
Pageof 61
Neurosurgery|July 17, 2018
Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype GlioblastomaDrew Pratt, Gifty Dominah, Graham Lobel, et al.
Leukemia Research|August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles, Eric J Feldman, Gail J Roboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemiaH M Kantarjian, S O'Brien, T L Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responsesJorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Cancer|February 6, 2003
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Leukemia|July 16, 2011
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaJ E Lancet, F Ravandi, R M Ricklis, et al.
Leukemia|December 14, 2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, et al.
The Oncologist|March 15, 2019
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung CancerYoung Kwang Chae, Andrew A Davis, Sarita Agte, et al.
Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levelsDevalingam Mahalingam, Ernest C Medina, Juan A Esquivel, et al.
Pageof 61